Phathom Pharmaceuticals, Inc.
PHATNASDAQHealthcare● Active
$10.00
$-0.13(-1.28%)
Market Cap$797559000
P/E Ratio—
52W High$18.31
52W Low$4.471
Phathom Pharmaceuticals, Inc. (PHAT) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
PHAT · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 30, 2026EPS Actual
-$0.37
Est. -$0.27 · -37.0%
Revenue
$0.06B
Est. $0.06B · +4.3%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 30, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
PHAT reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.20 | — | — | — | $0.07B | — |
| ▼ Q2 FY2026 | Apr 30, 2026 | -$0.27 | -$0.37 | -37.0% | $0.06B | $0.06B | +4.3% |
| ▲ Q1 FY2026 | Feb 26, 2026 | -$0.32 | -$0.16 | +49.9% | $0.06B | $0.06B | +0.7% |
| ▲ Q4 FY2025 | Oct 30, 2025 | -$0.30 | -$0.15 | +50.0% | $0.05B | $0.06B | -13.8% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -$0.76 | -$0.79 | -4.0% | $0.04B | $0.05B | -15.6% |
| — Q2 FY2025 | May 1, 2025 | -$1.06 | -$1.07 | -0.9% | $0.03B | $0.04B | -20.0% |
| ▲ Q1 FY2025 | Mar 6, 2025 | -$1.29 | -$0.79 | +38.8% | $0.03B | $0.03B | +2.1% |
| ▲ Q4 FY2024 | Nov 7, 2024 | -$1.57 | -$1.32 | +15.9% | $0.02B | $0.03B | -36.5% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.20
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 30, 2026Miss
EPS Actual
-$0.37
EPS Est.
-$0.27
EPS Surpr.
-37.0%
Revenue
$0.06B
Q1 FY2026
Feb 26, 2026Beat
EPS Actual
-$0.16
EPS Est.
-$0.32
EPS Surpr.
+49.9%
Revenue
$0.06B
Q4 FY2025
Oct 30, 2025Beat
EPS Actual
-$0.15
EPS Est.
-$0.30
EPS Surpr.
+50.0%
Revenue
$0.05B
Q3 FY2025
Aug 7, 2025Miss
EPS Actual
-$0.79
EPS Est.
-$0.76
EPS Surpr.
-4.0%
Revenue
$0.04B
Q2 FY2025
May 1, 2025
EPS Actual
-$1.07
EPS Est.
-$1.06
EPS Surpr.
-0.9%
Revenue
$0.03B
Q1 FY2025
Mar 6, 2025Beat
EPS Actual
-$0.79
EPS Est.
-$1.29
EPS Surpr.
+38.8%
Revenue
$0.03B
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
-$1.32
EPS Est.
-$1.57
EPS Surpr.
+15.9%
Revenue
$0.02B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.84 | $0.87 | $0.90 | 1 |
| Q3 FY2028 | $0.68 | $0.70 | $0.73 | 1 |
| Q2 FY2028 | $0.54 | $0.56 | $0.58 | 1 |
| Q1 FY2028 | $0.39 | $0.40 | $0.42 | 1 |
| Q4 FY2027 | $0.53 | $0.55 | $0.57 | 1 |
| Q3 FY2027 | $0.37 | $0.38 | $0.39 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.2B | $0.2B | $0.2B | 1 |
| Q3 FY2028 | $0.2B | $0.2B | $0.2B | 1 |
| Q2 FY2028 | $0.2B | $0.2B | $0.2B | 1 |
| Q1 FY2028 | $0.1B | $0.2B | $0.2B | 1 |
| Q4 FY2027 | $0.2B | $0.2B | $0.2B | 2 |
| Q3 FY2027 | $0.1B | $0.1B | $0.1B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | Apr 30, 2026 | -37.0% | $11.78 | $11.20 | -4.92% |
| ▲ Q1 FY2026 | Feb 26, 2026 | +49.9% | $12.32 | $13.56 | +10.06% |
| ▲ Q4 FY2025 | Oct 30, 2025 | +50.0% | $13.53 | $13.31 | -1.63% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -4.0% | $8.68 | $9.40 | +8.29% |
| ▲ Q2 FY2025 | May 1, 2025 | -0.9% | $4.29 | $3.36 | -21.68% |
| ▲ Q1 FY2025 | Mar 6, 2025 | +38.8% | $6.08 | $5.90 | -2.96% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +15.9% | $18.00 | $18.50 | +2.78% |
| ▼ Q3 FY2024 | Aug 8, 2024 | -4.2% | $10.81 | $11.75 | +8.70% |
Q2 FY2026-4.92%
Report Date
Apr 30, 2026
EPS Beat/Miss
-37.0%
Price Before
$11.78
Price After
$11.20
Q1 FY2026+10.06%
Report Date
Feb 26, 2026
EPS Beat/Miss
+49.9%
Price Before
$12.32
Price After
$13.56
Q4 FY2025-1.63%
Report Date
Oct 30, 2025
EPS Beat/Miss
+50.0%
Price Before
$13.53
Price After
$13.31
Q3 FY2025+8.29%
Report Date
Aug 7, 2025
EPS Beat/Miss
-4.0%
Price Before
$8.68
Price After
$9.40
Q2 FY2025-21.68%
Report Date
May 1, 2025
EPS Beat/Miss
-0.9%
Price Before
$4.29
Price After
$3.36
Q1 FY2025-2.96%
Report Date
Mar 6, 2025
EPS Beat/Miss
+38.8%
Price Before
$6.08
Price After
$5.90
Q4 FY2024+2.78%
Report Date
Nov 7, 2024
EPS Beat/Miss
+15.9%
Price Before
$18.00
Price After
$18.50
Q3 FY2024+8.70%
Report Date
Aug 8, 2024
EPS Beat/Miss
-4.2%
Price Before
$10.81
Price After
$11.75
Avg Beat Reaction-2.69%
Avg Miss Reaction+4.02%
Beat Rate5 / 8 quarters
Largest Move-21.68% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: PHAT ends December
Phathom Pharmaceuticals, Inc. (PHAT) most recently reported earnings on April 30, 2026 for Q2 FY2026, posting EPS of $-0.37 — missing the analyst consensus of $-0.27 by -37.0%. The next PHAT earnings date is expected around September 1, 2026.
Each quarter, investors track PHAT earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. PHAT revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
PHAT's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
PHAT earnings · 5 questionsPhathom Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. PHAT typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; PHAT historically reports after market close (AMC).
PHAT earnings datewhen is PHAT earningsPHAT next earnings datewhen does PHAT report earningsPHAT earnings calendar
▸ Source: FMP · Phathom Pharmaceuticals, Inc. SEC filings · US GAAP · Phathom Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026